AU2016341178B2 - Cytotoxic immunostimulating particles and uses thereof - Google Patents

Cytotoxic immunostimulating particles and uses thereof Download PDF

Info

Publication number
AU2016341178B2
AU2016341178B2 AU2016341178A AU2016341178A AU2016341178B2 AU 2016341178 B2 AU2016341178 B2 AU 2016341178B2 AU 2016341178 A AU2016341178 A AU 2016341178A AU 2016341178 A AU2016341178 A AU 2016341178A AU 2016341178 B2 AU2016341178 B2 AU 2016341178B2
Authority
AU
Australia
Prior art keywords
rna
particles
protamine
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016341178A
Other languages
English (en)
Other versions
AU2016341178A1 (en
Inventor
Steve Pascolo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biontech SE
Original Assignee
Biontech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech SE filed Critical Biontech SE
Publication of AU2016341178A1 publication Critical patent/AU2016341178A1/en
Application granted granted Critical
Publication of AU2016341178B2 publication Critical patent/AU2016341178B2/en
Assigned to BioNTech SE reassignment BioNTech SE Request to Amend Deed and Register Assignors: BIONTECH AG
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2016341178A 2015-10-21 2016-10-20 Cytotoxic immunostimulating particles and uses thereof Active AU2016341178B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2015/074386 WO2017067592A1 (en) 2015-10-21 2015-10-21 Cytotoxic immunostimulating particles and uses thereof
AUPCT/EP2015/074386 2015-10-21
PCT/EP2016/075146 WO2017068013A1 (en) 2015-10-21 2016-10-20 Cytotoxic immunostimulating particles and uses thereof

Publications (2)

Publication Number Publication Date
AU2016341178A1 AU2016341178A1 (en) 2018-04-12
AU2016341178B2 true AU2016341178B2 (en) 2023-02-23

Family

ID=54478716

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016341178A Active AU2016341178B2 (en) 2015-10-21 2016-10-20 Cytotoxic immunostimulating particles and uses thereof

Country Status (6)

Country Link
US (2) US10980875B2 (enExample)
EP (1) EP3365010B1 (enExample)
JP (2) JP7098520B2 (enExample)
AU (1) AU2016341178B2 (enExample)
CA (1) CA3002288C (enExample)
WO (2) WO2017067592A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017067592A1 (en) 2015-10-21 2017-04-27 Biontech Ag Cytotoxic immunostimulating particles and uses thereof
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
SG11202101732WA (en) 2018-10-01 2021-03-30 Univ Mainz Johannes Gutenberg Rna particles comprising polysarcosine
WO2021001023A1 (en) * 2019-07-02 2021-01-07 Biontech Rna Pharmaceuticals Gmbh Rna formulations suitable for therapy
CN113577039A (zh) * 2021-07-01 2021-11-02 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 鱼精蛋白压缩dna后被红细胞膜包裹构成的纳米颗粒的应用及其制备方法
WO2025196322A2 (en) 2024-03-22 2025-09-25 BioNTech SE Cytotoxic polynucleotides, particles containing the cytotoxic polynucleotides and uses thereof
CN118845677B (zh) * 2024-07-09 2025-10-10 常州大学 一种阿霉素无定形固体分散体及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100310583A1 (en) * 2007-01-31 2010-12-09 Immune Disease Institute Let-7 microrna and mimetics thereof as therapeutics for cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
KR100334858B1 (ko) 1993-02-19 2006-01-27 니뽄 신야쿠 가부시키가이샤 핵산공중합체를함유하는의약조성물
US5457187A (en) * 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
CA2638906A1 (en) 2006-01-26 2007-08-16 University Of Massachusetts Rna interference agents for therapeutic use
JP4936312B2 (ja) 2006-07-20 2012-05-23 株式会社島津製作所 新規な両親媒性物質、それを用いた薬剤搬送システム及び分子イメージングシステム
EP2200639B1 (en) 2007-09-24 2016-03-30 Government of the USA, as Represented by the Secretary, Department of Health and Human Services Immunostimulatory combinations of tlr3 ligands with tlr2 and tlr9 agonists and methods of use
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
US20110123637A1 (en) 2008-05-26 2011-05-26 Universitat Zurich Protamine/rna nanoparticles for immunostimulation
WO2010037408A1 (en) * 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US20110300205A1 (en) 2009-07-06 2011-12-08 Novartis Ag Self replicating rna molecules and uses thereof
WO2011069529A1 (en) * 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
BR112014004544A2 (pt) 2011-08-31 2017-04-04 Mallinckrodt Llc modificação com peg de nanopartículas com h-fosfonatos
EP2942348B1 (en) 2014-05-07 2017-10-25 Johannes Gutenberg-Universität Mainz Thiol-protected amino acid derivatives and uses thereof
WO2016072500A1 (ja) 2014-11-08 2016-05-12 国立大学法人岡山大学 修飾ｒｎａを含有する分子集合体及びそれを用いたｒｎａ送達システム
WO2017067593A1 (en) 2015-10-21 2017-04-27 Biontech Ag Methods and means for inducing an immune response
WO2017067592A1 (en) 2015-10-21 2017-04-27 Biontech Ag Cytotoxic immunostimulating particles and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100310583A1 (en) * 2007-01-31 2010-12-09 Immune Disease Institute Let-7 microrna and mimetics thereof as therapeutics for cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAZUYA NAKAMURA, AMR S ABU LILA, MARIKO MATSUNAGA, YUSUKE DOI, TATSUHIRO ISHIDA, HIROSHI KIWADA: "A Double-modulation Strategy in Cancer Treatment With a Chemotherapeutic Agent and siRNA", MOLECULAR THERAPY, NO LONGER PUBLISHED BY ELSEVIER, vol. 19, no. 11, 30 November 2011 (2011-11-30), pages 2040 - 2047, XP055140616, ISSN: 15250016, DOI: 10.1038/mt.2011.174 *
ZHANG Y, PENG L, MUMPER R J, HUANG L.: "Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy.", BIOMATERIALS, ELSEVIER, AMSTERDAM, NL, vol. 34, no. 33, 1 November 2013 (2013-11-01), AMSTERDAM, NL , pages 8459 - 8468, XP002758099, ISSN: 0142-9612, DOI: 10.1016/j.biomaterials.2013.07.050 *

Also Published As

Publication number Publication date
US20180289797A1 (en) 2018-10-11
US20210205447A1 (en) 2021-07-08
WO2017068013A1 (en) 2017-04-27
CA3002288A1 (en) 2017-04-27
US12263215B2 (en) 2025-04-01
WO2017068013A9 (en) 2018-03-22
EP3365010C0 (en) 2024-01-03
JP7098520B2 (ja) 2022-07-11
JP2018535206A (ja) 2018-11-29
WO2017067592A1 (en) 2017-04-27
EP3365010B1 (en) 2024-01-03
US10980875B2 (en) 2021-04-20
CA3002288C (en) 2023-06-27
JP7250986B2 (ja) 2023-04-03
AU2016341178A1 (en) 2018-04-12
EP3365010A1 (en) 2018-08-29
JP2022130599A (ja) 2022-09-06

Similar Documents

Publication Publication Date Title
US12263215B2 (en) Cytotoxic immunostimulating particles and uses thereof
EP3758729B1 (en) Il-15 conjugates and uses thereof
US9636414B2 (en) Particles comprising single stranded RNA and double stranded RNA for immunomodulation
US20220347308A1 (en) Methods and means for inducing an immune response
JP2022554272A (ja) インターロイキン１０コンジュゲートおよびその使用
CA3202602A1 (en) Therapeutic rna for treating cancer
US20200268895A1 (en) Immunostimulating-Toxic RNA In Alkaline Earth Metal Formulation
CA3138430A1 (en) Microparticles and nanoparticles having sulfate groups on the surface
JP7520321B2 (ja) ＡタイプＣｐＧオリゴデオキシヌクレオチド含有脂質粒子
WO2025196322A2 (en) Cytotoxic polynucleotides, particles containing the cytotoxic polynucleotides and uses thereof
US10172960B2 (en) Particles comprising single stranded RNA and double stranded RNA for immunomodulation
US10729785B2 (en) Particles comprising protamine and RNA in combination with endosome destabilizing agents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: BIONTECH SE

Free format text: FORMER NAME(S): BIONTECH AG